ASCO 2019 Podcast: Highlights from Five Swiss Experts

Abstracts discussed in this podcast:

Melanoma

• Pires da Silva IED et al. Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. Abstract 9511
  https://meetinglibrary.asco.org/record/174187/abstract
• Weber JS et al. Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. Abstract 100
  https://meetinglibrary.asco.org/record/174917/abstract
• Tawbi HAH et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). Abstract #9501 https://meetinglibrary.asco.org/record/173427/abstract
• Fogarty G et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). Abstract 9500
  http://meetinglibrary.asco.org/content/258029-239
• Schadendorf D et al. Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. Abstract 9551
  https://meetinglibrary.asco.org/record/176201/abstract

Lung cancer

• Garon EB et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.Abstract LBA9015.
  https://meetinglibrary.asco.org/record/175606/abstract
• Gainor JF et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Abstract 9008
  https://meetinglibrary.asco.org/record/174550/abstract
• Cho BC et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). Abstract 9011
  https://meetinglibrary.asco.org/record/174706
• Paik PK et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. Abstract 9005
  https://meetinglibrary.asco.org/record/174241/abstract
• Wolf J et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Abstract 9004
  https://meetinglibrary.asco.org/record/173357/abstract
• Janne PA et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Abstract 9007
  https://meetinglibrary.asco.org/record/174631/abstract
• Nakagawa K et al. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Abstract 9000
  https://meetinglibrary.asco.org/record/173373/abstract
• Haura B et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). Abstract 9009
  https://meetinglibrary.asco.org/record/174459/abstract

Head and Neck Cancer

• Rischin D et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).Abstract 6000
  https://meetinglibrary.asco.org/record/171051/abstract

Genitourinary Cancers

• Rini B et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Abstract 4500
  https://meetinglibrary.asco.org/record/171839/abstract
• Mejean A et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. Abstract 4508
  https://meetinglibrary.asco.org/record/171837/abstract
• Petrylak DP et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. Abstract LBA4505
  https://meetinglibrary.asco.org/record/171836/abstract